Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Aug 14;18(30):4012-8.
doi: 10.3748/wjg.v18.i30.4012.

Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome

Philippe Ducrotté  1 , Prabha Sawant, Venkataraman Jayanthi
Affiliations
Randomized Controlled Trial

Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome

Philippe Ducrotté et al. World J Gastroenterol. .

Abstract

Aim: To assess the symptomatic efficacy of Lactobacillus plantarum 299v (L. plantarum 299v) (DSM 9843) for the relief of abdominal symptoms in a large subset of irritable bowel syndrome (IBS) patients fulfilling the Rome III criteria.

Methods: In this double blind, placebo-controlled, parallel-designed study, subjects were randomized to daily receive either one capsule of L. plantarum 299v (DSM 9843) or placebo for 4 wk. Frequency and intensity of abdominal pain, bloating and feeling of incomplete rectal emptying were assessed weekly on a visual analogue scale while stool frequency was calculated.

Results: Two hundred and fourteen IBS patients were recruited. After 4 wk, both pain severity (0.68 + 0.53 vs 0.92 + 0.57, P < 0.05) and daily frequency (1.01 + 0.77 vs 1.71 + 0.93, P < 0.05) were lower with L. plantarum 299v (DSM 9843) than with placebo. Similar results were obtained for bloating. At week 4, 78.1 % of the patients scored the L. plantarum 299v (DSM 9843) symptomatic effect as excellent or good vs only 8.1 % for placebo (P < 0.01).

Conclusion: A 4-wk treatment with L. plantarum 299v (DSM 9843) provided effective symptom relief, particularly of abdominal pain and bloating, in IBS patients fulfilling the Rome III criteria.

Keywords: Abdominal pain; Clinical trial; Irritable bowel syndrome; Lactobacillus plantarum 299v; Probiotics.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow-chart of the study. L. plantarum 299v: Lactobacillus plantarum 299v; FAS: Full analysis set; ITT: Intention to treat.
Figure 2
Figure 2
Changes in frequency and severity of symptoms in both groups. A: Abdominal pain; B: Bloating; C: Feeling of incomplete evacuation. L. plantarum (DSM 9843): Lactobacillus plantarum 299v. aP < 0.05 vs baseline group.
Figure 3
Figure 3
Changes in stool frequency in both groups. L. plantarum (DSM 9843): Lactobacillus plantarum 299v. aP < 0.05 vs baseline group.
Figure 4
Figure 4
Overall assessment of the treatment efficacy by the patients and by the investigators.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, Talley NJ, Quigley EM. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104 Suppl 1:S1–35. - PubMed
    1. Jones J, Boorman J, Cann P, Forbes A, Gomborone J, Heaton K, Hungin P, Kumar D, Libby G, Spiller R, et al. British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut. 2000;47 Suppl 2:ii1–i19. - PMC - PubMed
    1. Mertz HR. Irritable bowel syndrome. N Engl J Med. 2003;349:2136–2146. - PubMed
    1. Quigley EM, Flourie B. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil. 2007;19:166–172. - PubMed
    1. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol. 2008;14:2650–2661. - PMC - PubMed

Publication types